G Medical Innovations (ASX:GMV) - CEO, Dr Yacov Geva
CEO, Dr Yacov Geva
Source: Finance News Network
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Telehealth company G Medical Innovations (GMV) has received firm commitments to undertake a $5 million placement
  • To raise the funds, 100 million fully-paid ordinary shares will now be issued to institutional and professional investors at a price of five cents each
  • Shares are expected to issue on or around August 13
  • The company will use the funds to scale-up its Independent Diagnostic Testing Facility (IDTF) operations and increase the manufacturing capabilities of the Prizma device and G Medical Patch
  • The money will also go towards increasing its U.S. sales team
  • G Medical is down 14.3 per cent and shares are currently trading for 5.4 cents each

Telehealth company G Medical Innovations (GMV) has received firm commitments to undertake a $5 million placement.

The company entered a trading halt on Wednesday but did not know how much it would be raising at the time.

To raise the funds, 100 million fully-paid ordinary shares will now be issued to institutional and professional investors at a price of five cents each.

Shares are expected to issue on or around August 13.

G Medical will use the money to scale-up its Independent Diagnostic Testing Facility (IDTF) operations, increase the manufacturing capabilities of the Prizma device and G Medical Patch, and increase its U.S. sales team.

“We now have the financial capacity to fast-track IDTF’s growth and fund greater manufacturing volumes for the Prizma and the Patch in anticipation of more purchase orders,” CEO, Dr Yacov Geva said.

“We will provide shareholders with an update as these matters progress,” Yacov said.

G Medical is down 14.3 per cent and shares are trading for 5.4 cents each at 12:54 pm AEST.

GMV by the numbers
More From The Market Online

Inoviq closes the gap on blood test results for ovarian cancer

INOVIQ has announced encouraging blood test identification results for ovarian cancer – cancer-positive tests saw a…

Paradigm Biopharma on track to US Phase III osteo program

Paradigm Biopharma has announced its completion of a submission to the US FDA to progress to…

Firebrick Pharma’s US launch of Nasal Spray is nothing to be sneezed at

Australian pharmaceutical developer, Firebrick Pharma (ASX:FRE) has launched its latest product, Nasodine Nasal Spray, in the…